Search Results - "Hurrish, Katie H"

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro by Hurrish, Katie H, Su, Yongwei, Patel, Shraddha, Ramage, Cassandra L, Zhao, Jianlei, Temby, Brianna R, Carter, Jenna L, Edwards, Holly, Buck, Steven A, Wiley, Sandra E, Hüttemann, Maik, Polin, Lisa, Kushner, Juiwanna, Dzinic, Sijana H, White, Kathryn, Bao, Xun, Li, Jing, Yang, Jay, Boerner, Julie, Hou, Zhanjun, Al-Atrash, Gheath, Konoplev, Sergej N, Busquets, Jonathan, Tiziani, Stefano, Matherly, Larry H, Taub, Jeffrey W, Konopleva, Marina, Ge, Yubin, Baran, Natalia

“…Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients…”
Get full text

Abstract 3785: ME-344, a novel isoflavone mitochondrial inhibitor, in combination with venetoclax constitutes a new metabolism-targeted approach to overcome resistance to Bcl-2 inhibition and standard of care treatment in AML by Hurrish, Katie H., Su, Yongwei, Patel, Shraddha, Wiley, Sandra E., Hou, Zhanjun, Carter, Jenna, Kalpage, Hasini, Hüttemann, Maik, Weng, Connie, Edwards, Holly, Polin, Lisa, Li, Jing, Yang, Jay, Matherly, Larry H., Konoplev, Sergej Naumovich, Taub, Jeffrey W., Konopleva, Marina, Ge, Yubin, Baran, Natalia

“…Abstract Acute myeloid Leukemia (AML) is an aggressive hematologic malignancy with poor prognosis. Despite chromosomal and genetic heterogeneity, AML are…”
Get full text